175 related articles for article (PubMed ID: 36973520)
1. Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Hoffmann L; Coras R; Kobow K; López-Rivera JA; Lal D; Leu C; Najm I; Nürnberg P; Herms J; Harter PN; Bien CG; Kalbhenn T; Müller M; Pieper T; Hartlieb T; Kudernatsch M; Hamer H; Brandner S; Rössler K; Blümcke I; Jabari S
Acta Neuropathol; 2023 Jun; 145(6):815-827. PubMed ID: 36973520
[TBL] [Abstract][Full Text] [Related]
2. Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma.
Wang Y; Wang L; Blümcke I; Zhang W; Fu Y; Shan Y; Piao Y; Zhao G
Brain Pathol; 2022 Jan; 32(1):e13011. PubMed ID: 34355449
[TBL] [Abstract][Full Text] [Related]
3. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020.
Slegers RJ; Blumcke I
Acta Neuropathol Commun; 2020 Mar; 8(1):27. PubMed ID: 32151273
[TBL] [Abstract][Full Text] [Related]
4. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
5. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
Ko JM; Kim JM; Kim GH; Yoo HW
J Hum Genet; 2008; 53(11-12):999-1006. PubMed ID: 19020799
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.
Papadopoulos G; Papadopoulou A; Kosma K; Papadimitriou A; Papaevangelou V; Kanaka-Gantenbein C; Bountouvi E; Kitsiou-Tzeli S
Eur J Pediatr; 2022 Oct; 181(10):3691-3700. PubMed ID: 35904599
[TBL] [Abstract][Full Text] [Related]
7. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
8. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
[TBL] [Abstract][Full Text] [Related]
9. Review: Challenges in the histopathological classification of ganglioglioma and DNT: microscopic agreement studies and a preliminary genotype-phenotype analysis.
Blümcke I; Coras R; Wefers AK; Capper D; Aronica E; Becker A; Honavar M; Stone TJ; Jacques TS; Miyata H; Mühlebner A; Pimentel J; Söylemezoğlu F; Thom M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):95-107. PubMed ID: 30326153
[TBL] [Abstract][Full Text] [Related]
10. Activating Mutations in
Takada M; Smyth LA; Thaiwong T; Richter M; Corner SM; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31277422
[TBL] [Abstract][Full Text] [Related]
11. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Siegfried A; Cances C; Denuelle M; Loukh N; Tauber M; Cavé H; Delisle MB
Am J Med Genet A; 2017 Apr; 173(4):1061-1065. PubMed ID: 28328117
[TBL] [Abstract][Full Text] [Related]
12. Detection of brain somatic variation in epilepsy-associated developmental lesions.
Bedrosian TA; Miller KE; Grischow OE; Schieffer KM; LaHaye S; Yoon H; Miller AR; Navarro J; Westfall J; Leraas K; Choi S; Williamson R; Fitch J; Kelly BJ; White P; Lee K; McGrath S; Cottrell CE; Magrini V; Leonard J; Pindrik J; Shaikhouni A; Boué DR; Thomas DL; Pierson CR; Wilson RK; Ostendorf AP; Mardis ER; Koboldt DC
Epilepsia; 2022 Aug; 63(8):1981-1997. PubMed ID: 35687047
[TBL] [Abstract][Full Text] [Related]
13. Clinical variability of neurofibromatosis 1: A modifying role of cooccurring PTPN11 variants and atypical brain MRI findings.
D'Amico A; Rosano C; Pannone L; Pinna V; Assunto A; Motta M; Ugga L; Daniele P; Mandile R; Mariniello L; Siano MA; Santoro C; Piluso G; Martinelli S; Strisciuglio P; De Luca A; Tartaglia M; Melis D
Clin Genet; 2021 Nov; 100(5):563-572. PubMed ID: 34346503
[TBL] [Abstract][Full Text] [Related]
14. Correction to: Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.
Hoffmann L; Coras R; Kobow K; López-Rivera JA; Lal D; Leu C; Najm I; Nürnberg P; Herms J; Harter PN; Bien CG; Kalbhenn T; Müller M; Pieper T; Hartlieb T; Kudernatsch M; Hamer H; Brandner S; Rössler K; Blümcke I; Jabari S
Acta Neuropathol; 2023 Jun; 145(6):851-855. PubMed ID: 37115209
[No Abstract] [Full Text] [Related]
15. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K; Horvat A; Strömbeck B; Nilsson F; Heldrup J; Behrendtz M; Forestier E; Andersson A; Fioretos T; Johansson B
Genes Chromosomes Cancer; 2008 Jan; 47(1):26-33. PubMed ID: 17910045
[TBL] [Abstract][Full Text] [Related]
16. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
Lee ST; Ki CS; Lee HJ
Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
[TBL] [Abstract][Full Text] [Related]
18.
Kakkar A; Majumdar A; Pathak P; Kumar A; Kumari K; Tripathi M; Sharma MC; Suri V; Tandon V; Chandra SP; Sarkar C
Neurol India; 2017; 65(5):1076-1082. PubMed ID: 28879901
[TBL] [Abstract][Full Text] [Related]
19. Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
Brasil AS; Malaquias AC; Wanderley LT; Kim CA; Krieger JE; Jorge AA; Pereira AC; Bertola DR
Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):717-22. PubMed ID: 21340158
[TBL] [Abstract][Full Text] [Related]
20. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Ekvall S; Hagenäs L; Allanson J; Annerén G; Bondeson ML
Am J Med Genet A; 2011 Jun; 155A(6):1217-24. PubMed ID: 21548061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
